Organon & Co. Class Action: The Gross Law Firm Reminds Organon Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to misleading statements and a significant reduction in quarterly dividends, which led to a sharp decline in stock price [1][3]. Summary by Relevant Sections Class Action Details - Shareholders who purchased Organon shares between October 31, 2024, and April 30, 2025, are encouraged to contact the firm for potential lead plaintiff appointment [1][4]. - The allegations include that the defendants made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding debt reduction after the acquisition of Dermavant [3]. Financial Impact - Following the revelation of the company's debt reduction strategy, Organon's regular quarterly dividend was reduced by 70%, causing the stock price to drop from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a decline of over 27% in one day [3]. Next Steps for Shareholders - The deadline for shareholders to register for the class action is July 22, 2025, and those who register will receive updates through a portfolio monitoring software [4]. - Participation in the case does not incur any cost or obligation for the shareholders [4]. Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [5].